The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

Biotech companies that will lead the next decade wont just have better science, theyll have superior operating models, writes ...

Hennion & Walsh CIO Kevin Mahn explains Morning Brief host Julie Hyman some of his investing outlooks for 2026, as he tries to "follow the money" on certain biotech and pharmaceutical trends. Also ...

aTyr Pharma's leading candidate is targeting a relatively large market with unmet needs. The biotech company is expected to release data from a phase 3 clinical trial soon. Though things look somewhat ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

Speculative investors and patience rarely go hand in hand. Nevertheless, if you’re looking to invest in the small-cap biotech sector, patience is a requirement. Most, if not all, of these companies ...

In the competitive world of small-cap biotechnology, CorMedix CRMD and Theravance Biopharma TBPH stand out as two companies working to turn scientific progress into lasting profits. Both companies, ...

Pulmonary sarcoidosis patients could soon get the treatment option they've been waiting for from aTyr Pharma. MoonLake Immunotherapeutics is running multiple phase 3 programs for its lead candidate.

Biotech stocks have staged an impressive rally over the past six months, with the XBI index – key benchmark for small and mid ...

Discover 2026 stock market outlook: earnings-driven gains, potential sector rotation, biotech opportunities, and Fed policy ...

The use of B-cell–depleting antibodies for autoimmune disease has been well validated with significant use of Roche Holdings AG (OTC:RHHBY) and Biogen Inc (NASDAQ:BIIB) partnered Rituxan (rituximab) ...